4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)

4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)

4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)

4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)

4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)

4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)

4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)

4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)

4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)

4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)

10-Q - Mind Medicine (MindMed) Inc. (0001813814) (Filer)

8-K - Mind Medicine (MindMed) Inc. (0001813814) (Filer)

424B3 - Mind Medicine (MindMed) Inc. (0001813814) (Filer)

8-K - Mind Medicine (MindMed) Inc. (0001813814) (Filer)

424B7 - Mind Medicine (MindMed) Inc. (0001813814) (Filer)

144 - Mind Medicine (MindMed) Inc. (0001813814) (Subject)

10-Q - Mind Medicine (MindMed) Inc. (0001813814) (Filer)

8-K - Mind Medicine (MindMed) Inc. (0001813814) (Filer)

8-K - Mind Medicine (MindMed) Inc. (0001813814) (Filer)

424B5 - Mind Medicine (MindMed) Inc. (0001813814) (Filer)

4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)

4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)

--On track to initiate the Phase 3 Voyage study of MM120 Orally Disintegrating Tablet (ODT) in Generalized Anxiety Disorder (GAD) in the fourth quarter of 2024; 12-week topline data anticipated in the first half of 2026-- --On track to initiate the Phase 3 Panorama study of MM120 ODT in GAD and the Phase 3 Emerge study of MM120 ODT in Major Depressive Disorder (MDD) in the first half of 2025-- --Cash and cash equivalents of $295.3 million as of September 30, 2024, expected to fund operations into 2027 and extend at least 12 months beyond the first Phase 3 topline data readout for MM120 ODT in GAD-- --Company to host a conference call today at 4:30 p.m. EST-- Mind Medicine (MindMed) Inc.

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it plans to host a conference call on Thursday, November 7, 2024, at 4:30 p.m. ET to provide a corporate update and review the Company's results for the third quarter ended September 30, 2024. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the Investor Relations section of the MindMed website, ir.mindmed.co, and archived for at least 30 days after

--Completed End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA); on track to initiate Phase 3 clinical program for MM120 orally disintegrating tablet (ODT) in Generalized Anxiety Disorder (GAD) in the second half of 2024-- --Expanding pipeline with MM120 ODT clinical program in Major Depressive Disorder (MDD) with plans to initiate a registrational study in first half of 2025-- --New patent issued by the United States Patent and Trademark Office (USPTO) extends intellectual property protection for MM120 ODT through 2041-- --Company to host a conference call today at 8:00 a.m. EDT-- Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it plans to host a conference call on Tuesday, August 13, 2024, at 8:00 a.m. ET to provide a corporate update and review the Company's results for the second quarter ended June 30, 2024. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the Investor Relations section of the MindMed website, https://ir.mindmed.co/, and archived for at least 30 days af

--Announced positive Phase 2b clinical trial results for MM120 in Generalized Anxiety Disorder (GAD), demonstrating clinically and statistically significant activity through 12 weeks after treatment-- --The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to MM120 for the treatment of GAD in adults-- --Cash and cash equivalents of $252.3 million as of March 31, 2024-- --Company to host a conference call today at 4:30 p.m. EDT-- Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its financial results for

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it plans to host a conference call on Wednesday, May 8, 2024, at 4:30 p.m. ET to provide a corporate update and review the Company's results for the first quarter ended March 31, 2024. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the Investor Relations section of the MindMed website, https://ir.mindmed.co/, and archived for at least 30 days afte

-A single oral administration of MM120 100 µg met its key secondary endpoint and maintained a clinically and statistically significant HAM-A reductions compared to placebo at 12 weeks with a 65% clinical response rate and 48% clinical remission rate- -MindMed plans to hold an End-of-Phase 2 meeting with the U.S. Food & Drug Administration (FDA) in the first half of 2024 and initiate its Phase 3 clinical program in the second half of 2024- -MindMed will host a webcast to discuss data from its Phase 2b study at 8:00 am ET- Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (Cboe Canada MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product cand

- Data update includes 12-week topline Phase 2b results for MM120 in Generalized Anxiety Disorder (GAD) - - Results from Phase 1 pharmacokinetics bridging trial for MM120 oral dissolving tablet (ODT) formulation to be discussed - Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (Cboe Canada: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will host a conference call and webcast on March 7, 2024. The program will provide an update on MM120 in Generalized Anxiety Disorder (GAD), including 12-week topline safety, efficacy, and durability results from the Company's Phase 2

--Announced statistically significant and clinically meaningful topline Phase 2b data for MM120 at 4 weeks in Generalized Anxiety Disorder (GAD)-- --Multiple planned milestones for MM120 in GAD, including 12-week Phase 2b data to be presented at March 7th investor event, and initiation of Phase 3 clinical program in second half of 2024-- --Initiated Phase 1 clinical trial of MM402 in Autism Spectrum Disorder (ASD)-- --Conference call to discuss year-end financial results at 8:00 a.m. EST-- Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (Cboe Canada:MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health d

– Trial met its primary endpoint with MM-120 demonstrating a statistically significant dose-dependent improvement in HAM-A scores four weeks after a single-dose – – MM-120 100 µg demonstrated a clinically and statistically significant HAM-A reduction of 21.3 points, representing a 7.6-point improvement over placebo at Week 4 (p=0.0004, Cohen's d effect size = 0.88) – – Clinical response rate of 78% in 100 µg and 200 µg dose groups and 50% clinical remission rate in the 100 µg dose group at Week 4 – – MM-120 was generally well-tolerated with mostly mild-to-moderate adverse events that occurred on dosing day – – Company plans to hold an End-of-Phase 2 meeting with the U.S. Food & Drug

Roth MKM analyst Jason Wittes maintains Mind Medicine (NASDAQ:MNMD) with a Buy and maintains $36 price target.

https://www.greenmarketreport.com/mdma-therapy-gets-support-from-prominent-research-group-as-fda-weighs-action/ The paper noted that MDMA therapies have been proven safe and effective by multiple studies.As an August deadline for the U.S. Food and Drug Administration looms regarding approval for psychedelic therapies, a coalition of well-known scientific researchers took it upon itself to publicize its support for midomafetamine (MDMA)-based treatment for patients with post-traumatic stress disorder.In an online consensus statement, 23 medical doctors and researchers urged the FDA to accept MDMA therapy for PTSD, noting that more than 17 U.S. military veterans commit suicide each day due to

https://www.marijuanamoment.net/california-legislature-approves-bill-to-break-psychedelics-research-logjam-sending-it-to-governor/

A promising new startup, Ovax Inc., secured $10 million in funding to advance the development of a groundbreaking vaccine designed to prevent fentanyl-related deaths. The initiative focuses on commercializing academic research aimed at preventing the potent opioid from reaching the brain, reported Bloomberg on Wednesday. Ovax obtained licensing for intellectual property from University of Houston researchers who successfully tested a fentanyl vaccine in rats. The company, which officially launches this week, is set to begin human trials early next year. If successful, the vaccine would block the euphoric effects and deadly overdoses caused by fentanyl. Unlike naloxone, which can r

Cantor Fitzgerald analyst Charles Duncan reiterates Mind Medicine (NASDAQ:MNMD) with a Overweight.

Rob Barrow, Chief Executive Officer of MindMed, said, "This marks a significant milestone for MindMed and for the millions of individuals affected by GAD. We are on schedule to initiate our Phase 3 clinical program for MM120 oral dissolving tablet (ODT) in GAD in the second half of this year and look forward to sharing additional details on the design of our pivotal program in the coming months."

https://www.marijuanamoment.net/oregons-first-in-nation-psilocybin-industry-is-struggling-to-find-paying-customers-a-year-after-launching/"Unfortunately we've seen one service center close down. I imagine there will be more, because very quickly it's going to get oversaturated."By Grant Stringer, Oregon Capital ChronicleA year in, Oregon's experiment with the first regulated psilocybin mushroom market in the world is short on customers.To attract them, advocates say the industry needs to get the word out about its benefits."We think everybody knows that psychedelics can help them because we're in this little bubble. But 99 percent of people have no idea what they could get out of a journey,"

A panel of advisors to the Food and Drug Administration (FDA) rejected MDMA as a treatment for post-traumatic stress disorder (PTSD) on Tuesday, citing a lack of evidence that the benefits would outweigh the risks of introducing the psychedelic treatment to patients. Most stocks in the psychedelic space took a hit on Wednesday as a result of the ruling.The panel voted 9-2 that MDMA, when combined with talk therapy, is not effective in treating PTSD. The panel also voted 10-1 that the current benefits do not outweigh the potential risks of using the drug to treat mental issues.Some members of the panel, like sociologist Elizabeth Joniak-Grant, pointed to allegations of misconduct in trials th

Leerink Partners resumed coverage of MindMed with a rating of Outperform and set a new price target of $20.00

ROTH MKM initiated coverage of MindMed with a rating of Buy and set a new price target of $36.00

Robert W. Baird initiated coverage of MindMed with a rating of Outperform and set a new price target of $27.00

Leerink Partners initiated coverage of MindMed with a rating of Outperform and set a new price target of $20.00

Canaccord Genuity initiated coverage of MindMed with a rating of Buy and set a new price target of $9.00

ROTH Capital resumed coverage of MindMed with a rating of Buy and set a new price target of $25.00

RBC Capital Mkts initiated coverage of MindMed with a rating of Outperform and set a new price target of $5.00

Oppenheimer initiated coverage of MindMed with a rating of Outperform and set a new price target of $3.50

Cantor Fitzgerald initiated coverage of MindMed with a rating of Overweight and set a new price target of $3.00

ROTH Capital initiated coverage of MindMed with a rating of Buy and set a new price target of $7.00

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Gregg A. Pratt, Ph.D., as Chief Regulatory and Quality Assurance Officer. Dr. Pratt will serve as a member of the Executive Committee and oversee the Company's regulatory and quality functions, as well as its product registration strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241118653031/en/(Photo: Business Wire) "We are thrilled to welcome Gregg to the MindMed team. His leadership will strengthen o

KaliVir Immunotherapeutics, Inc., a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, today announces the appointment of Schond Greenway as Chief Financial Officer (CFO). With more than 25 years of experience in corporate finance and investment analysis, Mr. Greenway has extensive biotechnology expertise, notably in navigating capital markets and spearheading successful fundraising initiatives. "We are thrilled to welcome Schond as our inaugural CFO. As we advance into clinical development with our lead program VET3-TGI, his proven track record in biotech finance and strategic leadership will be pivotal in steering KaliVir through our next

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Stephanie Fagan, effective today, as Chief Corporate Affairs Officer. Ms. Fagan will serve as a member of the executive team and will oversee public affairs and corporate communications for the Company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240729857388/en/Stephanie Fagan, Chief Corporate Affairs Officer of MindMed (Photo: Business Wire) "I want to welcome Stephanie to the MindMed team. Stephanie's track

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced today that as part of the annual reconstitution of the Russell stock indexes, the Company will be included in the Russell 2000® Index and the broad-market Russell 3000® Index, effective today. "MindMed's inclusion in the Russell Indexes mark an exciting milestone and reflects growing recognition of our commitment to addressing the unmet medical needs for people with brain health disorders by advancing MM120 for the treatment of general anxiety disorder and MM402 for the treatment of autism

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Mark R. Sullivan, effective today, as Chief Legal Officer and Corporate Secretary. "We are very excited to welcome Mark to our management team. Mark brings tremendous legal and public company life sciences expertise and will be a strong addition to our executive team. We believe Mark's experience, insights and guidance will prove invaluable as MindMed progresses to the next stage of its evolution. I look forward to working closely with Mark during this transf

NEW YORK, Aug. 12, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (NEO: MMED), (the "Company"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced the appointment of Dr. Suzanne Bruhn and Dr. Roger Crystal, effective August 11, 2022 as independent members of its Board of Directors. "We are pleased to welcome both Dr. Bruhn and Dr. Crystal to our Board. Their collective life sciences experience will be invaluable as we advance through several key product development inflection points in the com

FN Media Group Presents Microsmallcap.com Market Commentary NEW YORK, Aug. 10, 2022 /PRNewswire/ -- Toronto's Center for Addiction and Mental Health (CAMH) just received the first-ever federal grant to study whether the active component of "magic" mushrooms can be used to treat depression. Researchers will explore whether the psychoactive effects are necessary to relieve treatment-resistant depression in adults. According to CAMH's lead investigator, clinical trials suggest that psilocybin, combined with psychotherapy, can produce "sustained antidepressant effects" in individuals living with severe depression. This news comes just days after a major scientific review found "no clear evidence

NEW YORK, June 1, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (NEO: MMED), (the "Company" or "MindMed"), announces the voting results of the Company's annual general and special meeting of shareholders held on June 1, 2022 (the "Meeting"). Election of DirectorsThe five nominees of management were elected as directors at the Meeting. The voting results for the election of each director nominee are as follows: Name of Nominee Votes For Votes Withheld Number of Votes Percentage of Votes Number of Votes Percentage of Votes Carol A. Vallone 66,244,518.68 89.04%

NEW YORK, May 23, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (NEO: MMED) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, announced the appointment of Schond L. Greenway as Chief Financial Officer. Mr. Greenway comes to MindMed with over 20 years of experience in investment banking, finance and corporate advisory, and investment analysis in the life sciences sector. "We are very excited to add Schond to our management team. Schond brings extensive expertise in US biotech ca

- Dr. Lilienthal brings over 20 years of global biopharmaceutical experience, leading the development and commercialization of innovative medicines across multiple therapeutic areas including psychiatry and neurology - NEW YORK, April 5, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (NEO: MMED), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced the appointment of Francois Lilienthal, MD as Chief Commercial Officer. With more than two decades of global biopharmaceutical experience and after serving as a consultant for MindMed over the past six months, Dr. Lilienthal will step into this role to support the